ADXS isn't running trials on melanoma. The Phase 3 trial is on cervical cancer, and ADXS believes it has a case for potential conditional approval this year in Europe based on strong Phase 2 data. The other trials being run are for anal cancer, head & neck cancer, canine bone cancer, pediatric bone cancer and prostate cancer. The prostate cancer trial is a combo trial with Merck's Keytruda, and there is a combo trial on cervical cancer and head & neck cancer with Astra Zeneca's PD1. And there is also a recent $500 million deal with Amgen who is developing ADXS' personalized cancer treatment platform (NEO). In addition, ADXS recently began exploring infectious disease application for its listeria vaccine, inititating pre-clinical studies. A lot to be excited about, particularly at the current low valuation, great returns ahead for investors.
News 
Market Data 
Discover 
